Click here to get full coverage on Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus

Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics  GuruFocus

Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus

Click here to get full coverage on DTIL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

DTIL Stock News Today | Earnings, Events & Price Alerts  Intellectia AI

DTIL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Click here to get full coverage on Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis  Business Wire

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire

Click here to get full coverage on A great week that adds to Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns, institutional investors who own 46% must be happy - simplywall.st

A great week that adds to Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns, institutional investors who own 46% must be happy  simplywall.st

A great week that adds to Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns, institutional investors who own 46% must be happy - simplywall.st

Click here to get full coverage on Insider Purchase: Director at $DTIL Buys 3,000 Shares | DTIL Stock News - Quiver Quantitative

Insider Purchase: Director at $DTIL Buys 3,000 Shares | DTIL Stock News  Quiver Quantitative

Insider Purchase: Director at $DTIL Buys 3,000 Shares | DTIL Stock News - Quiver Quantitative

Click here to get full coverage on Precision Biosciences (DTIL) CFO logs RSU vesting and tax sell-to-cover - Stock Titan

Precision Biosciences (DTIL) CFO logs RSU vesting and tax sell-to-cover  Stock Titan

Precision Biosciences (DTIL) CFO logs RSU vesting and tax sell-to-cover - Stock Titan

Click here to get full coverage on Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last? - Yahoo Finance

Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?  Yahoo Finance

Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last? - Yahoo Finance

Click here to get full coverage on Precision BioSciences (NASDAQ:DTIL) Insider Sells $18,912.00 in Stock - MarketBeat

Precision BioSciences (NASDAQ:DTIL) Insider Sells $18,912.00 in Stock  MarketBeat

Precision BioSciences (NASDAQ:DTIL) Insider Sells $18,912.00 in Stock - MarketBeat

Click here to get full coverage on Precision Biosciences: Still Swinging And Finally Drawing Blood (NASDAQ:DTIL) - Seeking Alpha

Precision Biosciences: Still Swinging And Finally Drawing Blood (NASDAQ:DTIL)  Seeking Alpha

Precision Biosciences: Still Swinging And Finally Drawing Blood (NASDAQ:DTIL) - Seeking Alpha

Click here to get full coverage on Precision BioSciences Stock: Can This Tiny Gene-Editing Play Survive the Cash Crunch? - AD HOC NEWS

Precision BioSciences Stock: Can This Tiny Gene-Editing Play Survive the Cash Crunch?  AD HOC NEWS

Precision BioSciences Stock: Can This Tiny Gene-Editing Play Survive the Cash Crunch? - AD HOC NEWS

Click here to get full coverage on Scimeca, Precision Bio general counsel, sells $35,681 in DTIL stock - Investing.com

Scimeca, Precision Bio general counsel, sells $35,681 in DTIL stock  Investing.com

Scimeca, Precision Bio general counsel, sells $35,681 in DTIL stock - Investing.com

Click here to get full coverage on Precision BioSciences (DTIL) CEO logs RSU vesting and tax-driven share sale - Stock Titan

Precision BioSciences (DTIL) CEO logs RSU vesting and tax-driven share sale  Stock Titan

Precision BioSciences (DTIL) CEO logs RSU vesting and tax-driven share sale - Stock Titan

Click here to get full coverage on Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy - Yahoo Finance

Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy  Yahoo Finance

Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy - Yahoo Finance

Click here to get full coverage on Insider Sale: President and CEO of $DTIL Sells 34,799 Shares - Quiver Quantitative

Insider Sale: President and CEO of $DTIL Sells 34,799 Shares  Quiver Quantitative

Insider Sale: President and CEO of $DTIL Sells 34,799 Shares - Quiver Quantitative

Click here to get full coverage on Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares - MarketBeat

Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares  MarketBeat

Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares - MarketBeat

Click here to get full coverage on Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference  Business Wire

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire

Click here to get full coverage on Michael Amoroso (NASDAQ: DTIL) reports sale of 34,799 shares for $145,202 - Stock Titan

Michael Amoroso (NASDAQ: DTIL) reports sale of 34,799 shares for $145,202  Stock Titan

Michael Amoroso (NASDAQ: DTIL) reports sale of 34,799 shares for $145,202 - Stock Titan

Click here to get full coverage on Lynx1 discloses 4.1% Precision BioSciences (DTIL) stake in Schedule 13G/A - Stock Titan

Lynx1 discloses 4.1% Precision BioSciences (DTIL) stake in Schedule 13G/A  Stock Titan

Lynx1 discloses 4.1% Precision BioSciences (DTIL) stake in Schedule 13G/A - Stock Titan

Click here to get full coverage on Bleichroeder holds 8.21% of Precision Biosciences (DTIL) common stock - Stock Titan

Bleichroeder holds 8.21% of Precision Biosciences (DTIL) common stock  Stock Titan

Bleichroeder holds 8.21% of Precision Biosciences (DTIL) common stock - Stock Titan

Click here to get full coverage on One-time gene edit aims to fix root cause for most Duchenne patients - Stock Titan

One-time gene edit aims to fix root cause for most Duchenne patients  Stock Titan

One-time gene edit aims to fix root cause for most Duchenne patients - Stock Titan

Click here to get full coverage on $DTIL stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

$DTIL stock is down 10% today. Here's what we see in our data.  Quiver Quantitative

$DTIL stock is down 10% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock - MarketBeat

John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock  MarketBeat

John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock - MarketBeat

Click here to get full coverage on Precision BioSciences Inc (NASDAQ:DTIL) Stock Falls After Q3 2025 Earnings and Revenue Miss - ChartMill

Precision BioSciences Inc (NASDAQ:DTIL) Stock Falls After Q3 2025 Earnings and Revenue Miss  ChartMill

Precision BioSciences Inc (NASDAQ:DTIL) Stock Falls After Q3 2025 Earnings and Revenue Miss - ChartMill

Click here to get full coverage on Precision BioSciences (DTIL) wins FDA IND clearance for PBGENE-DMD Duchenne gene editing trial - Stock Titan

Precision BioSciences (DTIL) wins FDA IND clearance for PBGENE-DMD Duchenne gene editing trial  Stock Titan

Precision BioSciences (DTIL) wins FDA IND clearance for PBGENE-DMD Duchenne gene editing trial - Stock Titan

Click here to get full coverage on Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants - Business Wire

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants  Business Wire

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants - Business Wire

Click here to get full coverage on Precision Bio (NASDAQ: DTIL) shows HBV DNA editing in Phase 1; 66% HBsAg drop, no DLTs - Stock Titan

Precision Bio (NASDAQ: DTIL) shows HBV DNA editing in Phase 1; 66% HBsAg drop, no DLTs  Stock Titan

Precision Bio (NASDAQ: DTIL) shows HBV DNA editing in Phase 1; 66% HBsAg drop, no DLTs - Stock Titan

Click here to get full coverage on Precision BioSciences (DTIL) Price Target Decreased by 10.55% to 33.15 - MSN

Precision BioSciences (DTIL) Price Target Decreased by 10.55% to 33.15  MSN

Precision BioSciences (DTIL) Price Target Decreased by 10.55% to 33.15 - MSN

Click here to get full coverage on FDA fast-tracks gene-editing treatment for infants with rare liver disorder - Stock Titan

FDA fast-tracks gene-editing treatment for infants with rare liver disorder  Stock Titan

FDA fast-tracks gene-editing treatment for infants with rare liver disorder - Stock Titan

Click here to get full coverage on Precision BioSciences (DTIL) Exceeds Q3 Revenue Expectations - GuruFocus

Precision BioSciences (DTIL) Exceeds Q3 Revenue Expectations  GuruFocus

Precision BioSciences (DTIL) Exceeds Q3 Revenue Expectations - GuruFocus

Click here to get full coverage on Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 (NASDAQ:DTIL) - Seeking Alpha

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 (NASDAQ:DTIL)  Seeking Alpha

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 (NASDAQ:DTIL) - Seeking Alpha

Click here to get full coverage on Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates  Nasdaq

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq

Click here to get full coverage on Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates  Yahoo Finance

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update  Business Wire

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on Insider Buying: Stanley Frankel Acquires Additional Shares of Pr - GuruFocus

Insider Buying: Stanley Frankel Acquires Additional Shares of Pr  GuruFocus

Insider Buying: Stanley Frankel Acquires Additional Shares of Pr - GuruFocus

Click here to get full coverage on Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025 - Business Wire

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025  Business Wire

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025 - Business Wire

Click here to get full coverage on Precision BioSciences Announces Stock Offering and Warrants - TradingView

Precision BioSciences Announces Stock Offering and Warrants  TradingView

Precision BioSciences Announces Stock Offering and Warrants - TradingView

Click here to get full coverage on Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial - Business Wire

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial  Business Wire

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial - Business Wire

Click here to get full coverage on Precision BioSciences (DTIL) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $DTIL - MarketBeat

Precision BioSciences (DTIL) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $DTIL  MarketBeat

Precision BioSciences (DTIL) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $DTIL - MarketBeat

Click here to get full coverage on Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy - Business Wire

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy  Business Wire

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy - Business Wire

Click here to get full coverage on Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus

Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan  GuruFocus

Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus

Click here to get full coverage on DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - Yahoo Finance

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up  Yahoo Finance

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - Yahoo Finance

Click here to get full coverage on DTIL Forecast — Price Prediction for 2026. Should I Buy DTIL? - Intellectia AI

DTIL Forecast — Price Prediction for 2026. Should I Buy DTIL?  Intellectia AI

DTIL Forecast — Price Prediction for 2026. Should I Buy DTIL? - Intellectia AI

Click here to get full coverage on Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 - Business Wire

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025  Business Wire

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 - Business Wire

Click here to get full coverage on PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More  Quiver Quantitative

PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

Click here to get full coverage on Latham Represents Precision BioSciences in US$75 Million Offering of Common Stock, Pre-Funded Warrants, and Warrants - Latham & Watkins LLP

Latham Represents Precision BioSciences in US$75 Million Offering of Common Stock, Pre-Funded Warrants, and Warrants  Latham & Watkins LLP

Latham Represents Precision BioSciences in US$75 Million Offering of Common Stock, Pre-Funded Warrants, and Warrants - Latham & Watkins LLP

Click here to get full coverage on Precision BioSciences Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView

Precision BioSciences Inc reports results for the quarter ended September 30 - Earnings Summary  TradingView

Precision BioSciences Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView

Click here to get full coverage on Precision BioSciences Highlights 2026 Gene Editing Priorities - TipRanks

Precision BioSciences Highlights 2026 Gene Editing Priorities  TipRanks

Precision BioSciences Highlights 2026 Gene Editing Priorities - TipRanks

Click here to get full coverage on Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha

Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL)  Seeking Alpha

Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha

Click here to get full coverage on Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet - Yahoo Finance

Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet  Yahoo Finance

Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet - Yahoo Finance

Click here to get full coverage on DTIL - Precision Biosciences Latest Stock News & Market Updates - Stock Titan

DTIL - Precision Biosciences Latest Stock News & Market Updates  Stock Titan

DTIL - Precision Biosciences Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Precision BioSciences raises $75 million in stock and warrant offering By Investing.com - Investing.com Australia

Precision BioSciences raises $75 million in stock and warrant offering By Investing.com  Investing.com Australia

Precision BioSciences raises $75 million in stock and warrant offering By Investing.com - Investing.com Australia

Click here to get full coverage on Precision BioSciences Appoints Melinda Brown to Board of Directors - Precision BioSciences

Precision BioSciences Appoints Melinda Brown to Board of Directors  Precision BioSciences

Precision BioSciences Appoints Melinda Brown to Board of Directors - Precision BioSciences

Click here to get full coverage on Durham biotech trims staff to extend cash runway - The Business Journals

Durham biotech trims staff to extend cash runway  The Business Journals

Durham biotech trims staff to extend cash runway - The Business Journals

Click here to get full coverage on Precision BioSciences (DTIL) - Zacks Investment Research

Precision BioSciences (DTIL)  Zacks Investment Research

Precision BioSciences (DTIL) - Zacks Investment Research

Click here to get full coverage on Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week - Yahoo Finance

Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week  Yahoo Finance

Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week - Yahoo Finance

Click here to get full coverage on Precision BioSciences Appoints Michael Amoroso Chief Executive Officer - Precision BioSciences

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer  Precision BioSciences

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer - Precision BioSciences

Click here to get full coverage on Director’s Bold Move: A Strategic Investment in Precision BioSciences - TipRanks

Director’s Bold Move: A Strategic Investment in Precision BioSciences  TipRanks

Director’s Bold Move: A Strategic Investment in Precision BioSciences - TipRanks

Click here to get full coverage on DTIL Forecast — Price Target — Prediction for 2027 - TradingView

DTIL Forecast — Price Target — Prediction for 2027  TradingView

DTIL Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on Precision BioSciences - DTIL - Stock Price & News - The Motley Fool

Precision BioSciences - DTIL - Stock Price & News  The Motley Fool

Precision BioSciences - DTIL - Stock Price & News - The Motley Fool

Click here to get full coverage on Should I buy Precision BioSciences (DTIL) - Zacks Investment Research

Should I buy Precision BioSciences (DTIL)  Zacks Investment Research

Should I buy Precision BioSciences (DTIL) - Zacks Investment Research

Click here to get full coverage on DTIL Stock Price and Chart — NASDAQ:DTIL - TradingView

DTIL Stock Price and Chart — NASDAQ:DTIL  TradingView

DTIL Stock Price and Chart — NASDAQ:DTIL - TradingView

Click here to get full coverage on Dhunseri Tea & Industries Approves USD 1 Million Debenture Subscription in Subsidiary - scanx.trade

Dhunseri Tea & Industries Approves USD 1 Million Debenture Subscription in Subsidiary  scanx.trade

Dhunseri Tea & Industries Approves USD 1 Million Debenture Subscription in Subsidiary - scanx.trade

Click here to get full coverage on What date does Precision BioSciences's (DTIL) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research

What date does Precision BioSciences's (DTIL) report Earnings - Earnings Calendar & Announcement  Zacks Investment Research

What date does Precision BioSciences's (DTIL) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research

Click here to get full coverage on Precision BioSciences (DTIL) Short Interest & Short Float | Updated Mar 2026 $DTIL - MarketBeat

Precision BioSciences (DTIL) Short Interest & Short Float | Updated Mar 2026 $DTIL  MarketBeat

Precision BioSciences (DTIL) Short Interest & Short Float | Updated Mar 2026 $DTIL - MarketBeat

Click here to get full coverage on Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments - PR Newswire

Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments  PR Newswire

Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments - PR Newswire

Click here to get full coverage on Precision BioSciences (DTIL) Stock Price, News & Analysis $DTIL - MarketBeat

Precision BioSciences (DTIL) Stock Price, News & Analysis $DTIL  MarketBeat

DTIL

Price Chart

Key Statistics

Technicals

About DTIL

Latest News

Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus

DTIL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire

Advanced Charts

Top Gainers

Top Losers